Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Embrace disclosure, or kiss something else goodbye?

This article was originally published in Scrip

Executive Summary

Let's be clear: this is not a UK-only issue. However, the debate over clinical trial data disclosure has come to the boil this week in the UK, fuelled by the concentrated heat generated from the publication of Bad Pharma by Ben Goldacre, a book which levels criticism at the industry, regulators, doctors and academics for a wide range of issues including drug marketing practices, conflicts of interest and, to a large extent, data disclosure.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC019271

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel